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Improving response inhibition systems in
frontotemporal dementia with citalopram
Laura E. Hughes,1,2 Timothy Rittman,1 Ralf Regenthal,3 Trevor W. Robbins4,5 and
James B. Rowe1,2,5
Disinhibition is a cardinal feature of the behavioural variant of frontotemporal dementia, presenting as impulsive and impetuous
behaviours that are often difﬁcult to manage. The options for symptomatic treatments are limited, but a potential target for
therapy is the restoration of serotonergic function, which is both deﬁcient in behavioural variant frontotemporal dementia and
closely associated with inhibitory control. Based on preclinical studies and psychopharmacological interventions in other disorders,
we predicted that inhibition would be associated with the right inferior frontal gyrus and dependent on serotonin. Using magne-
toencephalography and electroencephalography of a Go-NoGo paradigm, we investigated the neural basis of behavioural disin-
hibition in behavioural variant frontotemporal dementia and the effect of selective serotonin reuptake inhibition on the neural
systems for response inhibition. In a randomized double-blinded placebo-controlled crossover design study, 12 patients received
either a single 30mg dose of citalopram or placebo. Twenty age-matched healthy controls underwent the same magnetoencepha-
lography/electroencephalography protocol on one session without citalopram, providing normative data for this task. In the
control group, successful NoGo trials evoked two established indices of successful response inhibition: the NoGo-N2 and
NoGo-P3. Both of these components were signiﬁcantly attenuated by behavioural variant frontotemporal dementia. Cortical
sources associated with successful inhibition in control subjects were identiﬁed in the right inferior frontal gyrus and anterior
temporal lobe, which have been strongly associated with behavioural inhibition in imaging and lesion studies. These sources were
impaired by behavioural variant frontotemporal dementia. Critically, citalopram enhanced the NoGo-P3 signal in patients, relative
to placebo treatment, and increased the evoked response in the right inferior frontal gyrus. Voxel-based morphometry conﬁrmed
signiﬁcant atrophy of inferior frontal gyrus, alongside insular, orbitofrontal and temporal cortex in our patient cohort. Together,
these data suggest that the dysfunctional prefrontal cortical systems underlying response inhibition deﬁcits in behavioural variant
frontotemporal dementia can be partially restored by increasing serotonergic neurotransmission. The results support a translational
neuroscience approach to impulsive neurological disorders and indicate the potential for symptomatic treatment of behavioural
variant frontotemporal dementia including serotonergic strategies to improve disinhibition.
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Abbreviations: bvFTD = behavioural variant of frontotemporal dementia; ERP = event-related potential; SSRI = selective sero-
tonin reuptake inhibitor
Introduction
Behavioural deﬁcits are a common and challenging aspect
of the behavioural variant of frontotemporal dementia
(bvFTD). Disinhibition, impulsivity and socially inappropri-
ate behaviour are core diagnostic features of this disorder,
together with stereotypical or perseverative actions, hyper-
orality, loss of empathy, apathy, and executive dysfunction
including cognitive inﬂexibility (Rascovsky et al., 2011). To
advance new treatments for disinhibition and impulsivity in
bvFTD, three requirements need to be addressed: ﬁrst, is to
understand the neural systems of these symptoms, drawing
on comparative studies and insights from healthy and pa-
tient groups. Second, is to identify pharmacological targets
for treatment based on the psychopharmacology of re-
sponse inhibition and the neurotransmitter deﬁcits in
bvFTD. Third, is to have a sensitive marker to measure
changes in the function of the neural systems underlying
behavioural disinhibition.
Impulsivity in neurological and neuropsychiatric disorders
is multifaceted, including premature and ill-considered ac-
tions, impaired behavioural restraint and suboptimal judge-
ments of risk and outcome that together can result in
adverse consequences. These different aspects of disinhib-
ition are likely to arise from deﬁcits in multiple cognitive
and emotional processes, associated with different struc-
tural and neurochemical abnormalities. Here, we focus on
one aspect of impulsivity, the deﬁcit in response inhibition.
The ability to inhibit an action is pivotal for self-control
enabling ﬂexible regulation of behaviour to withhold
planned or habitual actions until an appropriate context
or time. To examine response inhibition in bvFTD we
adopted a Go-NoGo paradigm in which ‘Go’ trials
induce a prepotent motor response that must be withheld
on ‘NoGo’ trials. This type of paradigm is included as part
of the frontal assessment battery, a sensitive measure of
frontal impairment: patients with bvFTD are typically im-
paired at this task, failing to inhibit responses and making
many commission errors (Dubois et al., 2000; Slachevsky
et al., 2004). However, performance can be variable and
patients with mild dementia are not always worse than
controls (Collette et al., 2007), suggesting that this task
may be useful to investigate the spectrum of disease severity
in bvFTD.
In health, NoGo inhibition recruits a broad cortical–
subcortical network including lateral prefrontal cortices,
anterior cingulate, premotor regions and subthalamic nu-
cleus (Rubia et al., 2001; Zheng et al., 2008; Swick et al.,
2011). Within this network, the right inferior frontal
gyrus has been identiﬁed as critical for inhibitory control
(Konishi et al., 1998, 1999; Aron et al., 2004, 2014;
Macoveanu et al., 2013) and inhibitory failures are
more common when this region is impaired after a lesion
(Aron et al., 2003; Kopp et al., 2013) or after transcranial
magnetic stimulation (Chambers et al., 2006). Comparably,
impulsive and disinhibited behaviours in bvFTD arise in
part from focal atrophy of frontal cortex (Williams et al.,
2005; Seeley et al., 2008; Kipps et al., 2009; Pereira et al.,
2009; Whitwell et al., 2009; Gordon et al., 2010; Rohrer
et al., 2010) together with abnormal frontolimbic (Farb
et al., 2013) and frontostriatal connectivity (O’Callaghan
et al., 2013a, b).
Successful response inhibition is also dependent on sero-
tonin (cf. Eagle et al., 2008). For example, in humans and
animals, serotonergic agonists enhance prefrontal responses
during inhibition (Anderson et al., 2002; Del-Ben et al.,
2005; Vollm et al., 2006), whilst depleting serotonin im-
pairs the ability to withhold a response (Harrison et al.,
1999; Eagle et al., 2009) and reduces prefrontal activation
(Rubia et al., 2005). Studies of individual differences, such
as genetic polymorphisms of the serotonin transporter or
trait serotonin receptor density in the normal population,
provide further evidence for the importance of serotonin
within the neural systems for response inhibition. For ex-
ample, NoGo paradigms have revealed that in healthy sub-
jects a susceptibility to impulsivity is due in part to genetic
variation in serotonergic systems and trait serotonergic
function (Nomura and Nomura, 2006; Beste et al., 2011;
Macoveanu et al., 2013). Patients with bvFTD have an
altered cerebral neurochemical proﬁle (Huey et al., 2006),
including severe reductions in the serotonergic innervation
of the forebrain (Yang and Schmitt, 2001), reduced 5HT1a
and 5HT2a receptors (Procter et al., 1999; Bowen et al.,
2008), and altered serotonergic receptor binding in the
frontal and temporal cortex (Sparks and Markesbery,
1991; Franceschi et al., 2005; Lanctot et al., 2007).
We propose that serotonergic deﬁciency and prefrontal
dysfunction are directly relevant to behavioural disinhib-
ition in bvFTD, and provide a compelling target for treat-
ment. Selective serotonin reuptake inhibitors (SSRIs) are an
attractive candidate therapy in this setting, given the well-
established proﬁle of safety and side-effects in adults.
Acutely, they increase the extracellular levels of serotonin
in the prefrontal cortex 4-fold (Bymaster et al., 2002).
SSRIs have been tested in a small number of open-label
studies of bvFTD (for review see Boxer and Boeve, 2007;
Freedman, 2007) with promising results, such as improve-
ment on the Neuropsychiatric Inventory (Swartz et al.,
1997; Lebert et al., 2004; Herrmann et al., 2012;) and
reduced stereotypical behaviours (Ikeda et al., 2004;
Mendez et al., 2005; Ishikawa et al., 2006). However,
not all SSRIs reveal consistent improvements, with
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paroxetine for example leading to mixed results (Moretti
et al., 2003; Deakin et al., 2004). Randomized placebo
controlled studies are required to further establish efﬁcacy
but such clinical studies would beneﬁt from evidence of the
engagement of residual inhibitory systems in bvFTD, in
addition to the preclinical evidence.
The potential effect of serotonergic therapies on disinhib-
ition is distinct from the common clinical use for affective
disorders. A beneﬁt in treating impulsivity has been shown
in the context of another neurological disorder associated
with milder impulsivity and moderate serotonin deﬁciency,
namely Parkinson’s disease (Ye et al., 2014), despite clear
differences in other aspects of the clinical syndrome.
Because the slowing or reversal of neuropathology and neur-
onal loss in bvFTD is not at present possible, pharmacological
manipulations that enhance serotonergic neurotransmitter
function offer a potential means of restoring the function of
brain networks underlying response inhibition.
To understand how serotonergic therapy with an SSRI
affects inhibitory systems, we studied the neurophysio-
logical signatures of successful NoGo trials using simultan-
eous magnetoencephalography (MEG) and
electroencephalography (EEG) in a double-blind crossover
study of citalopram. MEG and EEG are well tolerated by
patients with bvFTD and are sensitive to the impact of
bvFTD on local brain function and cortical networks
(Hughes et al., 2011, 2013; Hughes and Rowe, 2013).
Electrophysiological studies have consistently identiﬁed
two main components in the event-related potential (ERP)
that index successful inhibition: the NoGo-N2 (Falkenstein
et al., 2002; Nieuwenhuis et al., 2003; Falkenstein, 2006;
Huster et al., 2013, 2014; Smith et al., 2013) and the
NoGo-P3 (Band and van Boxtel, 1999; Roche et al.,
2005; Smith et al., 2008, 2013; Enriquez-Geppert et al.,
2010). While EEG represents spatial summation of con-
ducted neural activity, and is well suited to identifying
the time course of signiﬁcant components, MEG has the
potential advantage in localizing cortical sources. Inferior
frontal and temporal activity has been identiﬁed using
MEG in association with NoGo inhibition in healthy
adults (Vidal et al., 2012) and adolescents (Vara et al.,
2014). Moreover, electrophysiological measures are sensi-
tive to degenerative disease, with attenuated responses
during NoGo in inhibition in Parkinson’s disease (Bokura
et al., 2005) and Huntington’s disease (Beste et al., 2008).
Our principal hypothesis was that citalopram would re-
store the function of the deﬁcient systems for successful
inhibition in bvFTD, centred on the prefrontal cortex.
The advantage of MEG with EEG over simple behavioural
measures is not only to provide greater sensitivity to psy-
chopharmacological intervention, but also to enable cross-
validation of translational models of response inhibition
systems. The latter may be achieved, for example, by exam-
ining serotonergic modulation of frontostriatal systems of
inhibitory control in rats and non-human primates (cf.
Robbins, 2007; Cools et al., 2008). Such translational
cross-validation may thus facilitate the use of response
inhibition measures within clinical trials, especially where
they are also correlated with neuropsychological and eco-
logical measures of impulsivity.
We predicted that bvFTD would diminish the N2 and P3
components of the neurophysiological signature of response
inhibition, with reduced neuronal source currents especially
in the right inferior frontal and temporal regions. We also
predicted that citalopram would restore the function of
these frontal sources, in the context of serotonergic deple-
tion caused by bvFTD.
Materials and methods
Subjects
Twelve right-handed adult patients with progressive bvFTD
were recruited from the specialist FTD clinic at the
Cambridge University Hospitals NHS Trust, based on clinical
diagnostic criteria, including abnormal clinical imaging
(Rascovsky et al., 2011). Patients with non-progressive
mimics of bvFTD were not included (Kipps et al., 2010).
Subjects were excluded if they were prescribed serotonergic
reuptake inhibitors or if they had any contraindications to
MEG or citalopram. A screening electrocardiogram was per-
formed if a risk of cardiac disease was suggested by personal
medical history (e.g. hypertension) or family history (e.g. car-
diac disease). Twenty right-handed healthy older adults were
recruited from the volunteer panel of the MRC Cognition and
Brain Sciences Unit. No subjects in the control group had a
history of signiﬁcant neurological or psychiatric illness, nor
reported any cognitive symptoms. The study was approved
by the local Research Ethics Committee and exempted from
Clinical Trials status by the United Kingdom’s Medicines and
Healthcare products Regulatory Authority. All participants
gave written informed consent before participation according
to the 1991 Declaration of Helsinki.
Patients underwent neuropsychological assessment including
the revised Addenbrooke’s Cognitive Examination (ACE-r)
(Mioshi et al., 2006), Mini-Mental State Examination
(MMSE), the Hayling and Brixton Task (Burgess and
Shallice, 1997), the Graded Naming test and the revised
Beck Depression Inventory (BDI-II). On each session the
Kirby Temporal Discounting Test and a Visual Analogue
Scale were used to assess impulsivity and emotional state, re-
spectively. Caregivers completed the Cambridge Behavioural
Inventory (CBI) (Wedderburn et al., 2008) to provide an as-
sessment of the severity of behavioural symptoms. Patient and
control details are summarized in Table 1.
Experimental design
The bvFTD group were entered into a double-blind rando-
mized crossover design. Two sessions were conducted 2
weeks apart, in which patients were given either 3  10mg
oral tablets of citalopram or 3  10mg of placebo tablets.
Blood samples were taken 2 h after drug administration, im-
mediately before the MEG recording, close to the estimated
time of peak plasma concentration (Sangkuhl et al., 2011).
The relationship between peak plasma and peak CNS levels
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is complex, but based on animal studies (Cremers et al., 2009;
Karlsson et al., 2013) and observed midbrain SERT occupancy
in healthy human volunteers (Klein et al., 2006), we expected
peak CNS levels over this timeframe. Mean plasma levels after
citalopram, measured by a speciﬁc validated high performance
chromatographic method, were 38.6 ng/ml (range 23.8–
55.7 ng/ml) and after placebo, 0 ng/ml. Two patients did not
complete the citalopram session, one because of nausea and
one because of unexplained refusal, leaving 10 patients who
completed both sessions. Control subjects were assessed on
one occasion, for normative data and comparison with pa-
tients on placebo. Thus for the behavioural analyses, disease
effects (versus controls) were examined from the 12 patients
who completed the placebo session compared with the 20 con-
trols, and serotonergic effects (citalopram versus placebo) were
examined in the 10 patients who completed both sessions. The
MEG and EEG analysis (described below) included only suc-
cessful Go and NoGo trials. For the MEG/EEG results, two
patients did not have enough successful NoGo trials to be
included, leaving 10 patients on placebo to compare with con-
trols and nine patients for the repeated measures design.
Task
The Go-NoGo task comprised 400 visually cued Go trials and
104 visually cued NoGo trials, split into four equal blocks.
Presentation of stimuli was controlled using EPrime. Each
trial started with a white ﬁxation cross presented centrally
on a dark grey background for 2 s followed by the
presentation of a letter cue that subtended 0.8. Go trials
were cued with the letter ‘O’, presented centrally until the re-
sponse button was pressed, or until 1.5 s if no press was made.
NoGo trials were cued with the letter ‘X’ and were presented
for 1.5 s. Stimulus onset asynchrony was 3.5 s. Trial order was
pseudorandom, permuted such that on 15% of trials a NoGo
cue was presented after each of 1, 3, 5, and 7 Go trials, and on
5% of trials the NoGo cue was presented after each of 0, 2, 4,
6, and 8 Go trials. Participants were instructed to focus on a
small central ﬁxation cross and press a button with their right
hand as quickly as they could every time the Go cue appeared
and to withhold their press when the NoGo cue appeared.
Before the MEG recording all participants were given 40 prac-
tice trials, and conﬁrmed that they had understood the task.
EEG and MEG collection
MEG data were acquired continuously at 1 kHz in a
magnetically-shielded room with a 306-channel Vectorview
MEG system (Elekta Neuromag) that contained one magnet-
ometer and two orthogonal planar gradiometers at each of
102 positions. EEG data were recorded simultaneously using
a 70 electrode EEG ‘Easy Cap’, arranged according to the
international 10–20 system. During recording, electrodes
were referenced to the nose and the ground placed on the
left cheek. Vertical and horizontal electrooculograms were re-
corded using paired EOG electrodes. Five head position indi-
cator (HPI) coils were used to monitor head position. The 3D
locations of the HPI coils, 80 ‘head points’ across the scalp,
and three anatomical ﬁducials (the nasion and left and
right pre-auricular points), were recorded using a 3D digitizer
(Fastrak Polhemus Inc.).
Raw MEG data were initially preprocessed using MaxFilter
software (version 2.0, Elekta-Neuromag) with movement com-
pensation. Further preprocessing and data analysis of MEG
and EEG used SPM12. Data were down sampled to 500Hz,
eye blink artefacts were corrected using the Berg method of
artefact correction (a topography based artefact correction
method, Berg and Scherg, 1994). Data were band pass ﬁltered
between 0.1Hz and 40Hz and divided into epochs of 900ms
(100ms before stimuli onset to 800ms after) time locked to
the stimulus onset, and baseline corrected (100 to 0ms).
Epochs containing artefacts were rejected if the amplitudes ex-
ceeded the following thresholds: 2500 fT for magnetometers,
900 fT for gradiometers and 150mV for the EEG. After arte-
fact rejection the mean trial inclusions for the accurate Go and
NoGo conditions for the control group was 383 [standard
deviation (SD) = 44.2] and 94 (SD = 10); for the placebo ses-
sion 346 (SD = 73.9) and 85 (SD = 17.9), and the citalopram
session included 296 (SD = 109.3) and 77 (SD = 23.9), respect-
ively. Robust averaging was used to average epochs for the
successful Go trials and the successful NoGo trials.
MRI
A magnetization prepared rapid acquisition gradient echo
(MPRAGE) T1-weighted structural image was obtained from
each subject (repetition time 2250ms, echo time 2.99ms, ﬂip
angle 9, inversion time 900ms, 256  256  192 isotropic
1mm voxels) to co-register the MEG data and to enable sub-
ject speciﬁc modelling of the lead ﬁeld for the source analysis.
Table 1 Details of patients with bvFTD and healthy
control subjects
Controls Patients
Male/Female 8 m / 12f 6 m / 6f
Age 61.3 (9.32) 62.4 (6.0)
MMSE 29.6 (0.68) 24.1 (3.6)
ACE-r
Total (100) 97.5 (1.99) 67.4 (16.5)
Attention (18) 17.75 (0.55) 14.9 (2.7)
Memory (26) 25.35 (1.04) 15.7 (7.1)
Verbal fluency (14) 12.9 (1.33) 4.2 (3.0)
Language (26) 25.7 (0.55) 18.8 (6.6)
Visual Spatial (16) 15.7 (0.55) 13.7 (1.6)
Graded Naming 11.7 (8.9)
CBI
Total 116.7 (21.3)
Stereotypic and motor behaviours 14.2 (2.8)
Disinhibited phenotype scale* 40.4 (5.6)
Hayling
A + B Errors** 37.6 (27.5)
Values shown are group means [standard deviation (SD) in parentheses]. MMSE = 30
point Mini-Mental State Examination; ACE-r = Addenbrooke’s cognitive exam revised,
scored out of 100, divided into five subscales with total points for each in parentheses.
The Hayling score is the converted error score on section two ‘unconnected com-
pletion’ (out of a possible 128). Graded naming is number of errors out of 30;
CBI = Cambridge Behavioural Inventory.
*Composite sum from Cambridge Behavioural Inventory subscales including all items
from the disinhibited, challenging, motor, eating and insight subscales, and the euphoria
items from the mood subscale (Borroni et al., 2012).
**For comparison, O’Callaghan et al., (2013b) reported bvFTD patients A + B errors as
37.5 (19.7) and control A + B errors 1.4 (2.2).
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The T1 images were also used in a voxel-based morphometry
analysis to identify differences in grey matter volume between
the bvFTD and controls groups. For this method, SPM 12
(www.ﬁl.ion.ucl.ac.uk/spm) was used with the DARTEL tool-
box (Ashburner, 2007). The T1 image of each subject was
segmented into grey, white and CSF tissue classes and used
together to create a study-speciﬁc group template, which im-
proves the inter-subject alignment during normalization. The
template was registered to MNI space, and used to generate
Jacobian scaled modulated grey and white matter images from
each subject, which were spatially normalized to MNI space
and smoothed with an 8mm full-width at half-maximum
kernel. To examine differences between patients and controls,
t-tests within SPM’s general linear model were performed on
the grey and white images. Each model also included covari-
ates of age and total intracranial volumes to correct for inter-
subject differences in global brain volume. Statistical images
were thresholded with a cluster-based family-wise error
(FWE) correction P5 0.05 (after P50.001 voxel-wise uncor-
rected threshold).
Data analysis
Behavioural analyses examined mean reaction time for Go re-
sponses and incorrect NoGo responses and response accuracy
(arsine transformed) using IBM SPSS Statistics 22.0.
Independent two sample t-tests were used to compare the re-
action times of the 12 bvFTD patients on placebo and 20
controls, and Mann-Whitney U-tests were used for response
accuracy (due to non-Guassian distribution). To compare the
citalopram versus placebo sessions paired sample t-tests were
used for reaction times and non-parametric Wilcoxon Signed
Ranks test for response accuracy. Greenhouse-Geisser correc-
tion was used to correct for non-sphericity where necessary.
Spearman’s rank correlation coefﬁcient was calculated to esti-
mate the relationship between NoGo accuracy and the Hayling
scaled error score and the stereotypic and motor behaviours
score of the Cambridge Behavioural Inventory. To investigate
the relationship of NoGo disinhibition with general disin-
hibited behaviours, we also calculated a total ‘disinhibited/im-
pulsive’ score from the Cambridge Behavioural Inventory,
including the sum of all items from the disinhibited, challen-
ging, motor, eating and insight subscales, and the euphoria
items from the mood subscale. These speciﬁc types of behav-
iours have been shown previously to load onto a behavioural
‘disinhibition’ factor (Borroni et al., 2012).
For the ERPs, peak amplitude and peak latency were mea-
sured from three midline electrodes Fz, Cz and Pz, for three
ERP components: (i) the P2, the most positive peak after
150ms maximal at Fz, included to examine early sensory pro-
cesses preceding the N2; (ii) the N2, the most negative deﬂec-
tion after 200ms maximal at Cz; and (iii) the P3, the most
positive peak after 300ms maximal at Pz. To test for disease
effects, separate repeated measures ANOVAs were used to
examine peak amplitudes and peak latencies. The three ERP
components were included as the repeated measure (P2, N2
and P3) with subject group (bvFTD placebo versus controls) as
the between subjects factor. To test the effects of citalopram
treatment, a second set of repeated measures ANOVAs
included the between subjects factors: ERP component (P2,
N2 and P3) and drug (citalopram versus placebo), for the
bvFTD patients who completed both sessions. As the peak
amplitude for the N2 component is negative, absolute ampli-
tude rather than signed amplitude was included in the analysis.
Pairwise t-tests were Bonferroni corrected for multiple com-
parisons, and Greenhouse-Geisser corrected where
appropriate.
Group differences between the NoGo source waveform con-
tours were calculated time-point by time-point using two-
sample t-tests between the bvFTD and control groups, and
paired t-tests between the placebo and citalopram sessions
across a 200ms time window spanning the peak of each of
the three ERP components of interest. Differences were con-
sidered signiﬁcant if data points consecutively met the
P5 0.05 criterion for at least 22ms (11 data points with
500Hz sampling) (cf. Guthrie and Buchwald, 1991).
Analyses of the MEG data used the 204 gradiometer MEG
channels. Forward models were estimated using cortical
meshes based on coregistering the ﬁducials and head shape
points to the subject’s individual MRI scan. Inverse reconstruc-
tion was computed using the SPM12 ‘COH’ algorithm, com-
parable to standardized low-resolution brain electromagnetic
tomography (sLORETA, Pascual-Marqui, 2002), that esti-
mates distributed cortical responses across the entire brain
volume. Images were computed for each subject for the suc-
cessful Go and NoGo trials across the three time windows of
interest spanning the three peak ERP components: the P2 (100
to 200ms after stimuli onset), the N2 (250 to 350ms) and the
P3 (400 to 500ms), and also baseline images for each trial
type (100 to 0ms) to control for variance in between
group comparisons.
A ﬁrst set of general linear models included source images
for controls and bvFTD placebo for the Go trials, NoGo trials
and the baseline for each condition. Separate models were
generated for each time window. Contrasts for the controls
examined task performance (Go and NoGo trials versus base-
line) and NoGo inhibition (NoGo versus Go trials). Contrasts
of disease effects compared the bvFTD group with controls on
the NoGo trials (the interaction term: Controls versus
bvFTD  NoGo versus baseline).
A second set of general linear models tested the effects of
citalopram in a within-subjects design. These models included
images for citalopram and placebo sessions for the Go and
NoGo trials and the baseline for each condition. Separate
models were generated for each time window. Contrasts
tested for drug effects on general task performance (Go and
NoGo trials for citalopram versus placebo), and on NoGo
inhibition (citalopram versus placebo  NoGo versus
baseline).
Statistical maps of the normative data contrasts for the con-
trols were thresholded with a cluster-based family-wise error
correction P50.05 (after P5 0.001 voxel-wise uncorrected
threshold). Contrasts between controls and bvFTD, and be-
tween the citalopram and placebo sessions used an independ-
ent regions of interest analysis. Two regions of interest were
created using the Pickatlas ‘aal’ templates (Tzourio-Mazoyer
et al., 2002; Maldjian et al., 2003, 2004) to examine right
inferior frontal responses (including pars triangularis and
pars opercularis) and right temporal involvement in response
inhibition (masks are outlined in Fig. 3). These masks were
used for small volume correction for the time windows of
interest (P50.05 family-wise error corrected for multiple
comparisons). In view of possible activation differences outside
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of our regions of interest, whole-brain analyses at the explora-
tory threshold of P50.001 (uncorrected) are also reported.
Results
Behavioural results
Mean reaction times and accuracy rates (arcsine trans-
formed) for both Go and NoGo conditions are presented
in Table 2. For all subjects, mean reaction times of the
commission errors on NoGo trials were signiﬁcantly
faster than the reaction times for the Go trials [mean reac-
tion times: Controls: Go trials = 287.60ms, NoGo
trials = 222.39ms, t(18) = 5.7, P5 0.05; bvFTD placebo:
Go trials = 475.98ms NoGo trials = 369.04ms, t(8) = 2,
P50.05; bvFTD citalopram: Go trials = 538.81ms NoGo
trials = 332.03ms, t(9) = 4, P5 0.05] demonstrating a re-
sponse prepotency generated by the Go trials that must
be inhibited on successful NoGo trials.
Compared to controls, the bvFTD placebo group were
signiﬁcantly slower when responding to the Go trials
[t(30) = 5, P5 0.001] and they were slower when
making commission errors on the NoGo trials [t(26) =2.8,
P50.05]. The bvFTD placebo group also made signiﬁ-
cantly more omission errors on Go trials [mean Go accur-
acy: controls 99%, placebo 96%; U(30) = 20.5, P5 0.05],
but at a group level they did not make signiﬁcantly more
commission errors on NoGo trials compared to controls
[mean NoGo accuracy: controls 94%, placebo 80%;
U(30) = 100, P5 0.05].
Consistent with disinhibition underlying the commission
errors, NoGo accuracy in the bvFTD placebo group corre-
lated with the Hayling scaled error score (Spearman’s
rho = 0.52, P5 0.05) and the stereotypic and motor be-
haviours score of the Cambridge Behavioural Inventory
(Spearman’s rho = 0.68, P5 0.05), suggesting that pa-
tients with higher behavioural disinhibition on clinical
measures were more likely to respond in error on a
NoGo trial. The composite score of ‘general disinhibition’
calculated from the Cambridge Behavioural Inventory sub-
scales (cf. Borroni et al, 2012), correlated with NoGo ac-
curacy (Spearman’s rho = 0.57, P50.05), as did the
total score of the Cambridge Behavioural Inventory
(Spearman’s rho = 0.67, P50.05), suggesting that
increased ‘everyday’ behavioural disinhibition is associated
with more commission errors on the NoGo trials.
There were no signiﬁcant within-group serotonergic ef-
fects on accuracy or reaction times in bvFTD (this is con-
sistent with previous data in healthy subjects, cf.
Macoveanu et al., 2013). The patients’ behaviour may sug-
gest a poor trade-off between the two conditions: the slow
response and higher rate of omissions on the Go trials may
facilitate inhibition on NoGo trials. However, there was no
signiﬁcant correlation between Go reaction times and
NoGo accuracy (Spearman’s rho = 0.08 ns, bvFTD placebo,
Spearman’s rho = 0.01 ns, bvFTD citalopram) suggesting
that this was not the case.
Two patients performed poorly on the task, making a
majority of NoGo commission errors (mean 92% NoGo
errors). These two patients were excluded from further
MEG and EEG analyses, which needed a sufﬁcient number
of trials to examine successful NoGo responses. This con-
straint goes beyond the general issue of ‘scanning patients
with tasks they can perform’ (Price and Friston, 1999) and
reﬂects the need for good signal-to-noise, which is inﬂuenced
by the number of trials to obtain an accurate estimation of
the magneto- and electro-physiological indices.
Volumetric-based morphometry
The voxel-based morphometry conﬁrmed extensive grey
matter atrophy for the patient group in the bilateral tem-
poral poles, inferior and middle temporal gyrus, insula, in-
ferior and superior frontal gyrus and orbitofrontal gyrus
(Fig. 1). The atrophy measured by voxel-based morphom-
etry is indicative of underlying pathology, although the
presence of TARDBP (also known as TDP-43) or tau-posi-
tive inclusions cannot be measured or distinguished directly
using voxel-based morphometry.
EEG results
The analysis of the ERP data from the NoGo trials exam-
ined peak amplitude at three electrode sites (Fz, Cz, Pz) for
the three components of interest (P2, N2, P3). Figure 2
depicts the mean ERP waveforms at each electrode site.
In the bvFTD placebo group, peak amplitudes were dimin-
ished compared to controls, [F(1,24) = 27.05, P5 0.05],
and pairwise t-tests revealed these differences as signiﬁcant
for the N2 at Cz (mean difference = 3.8mV, SE = 1.7,
P5 0.05) and P3 at Pz (mean difference = 6.4 mV,
SE = 1.5, P5 0.001), but not the P2 at Fz (mean
difference = 2.1mV, SE = 1.4, P = not signiﬁcant). There
were no signiﬁcant latency differences between the controls
and placebo group, suggesting that although peak ampli-
tudes are reduced, the peaks are not occurring signiﬁcantly
later in the patient group.
Comparisons of peak amplitudes between the placebo and
citalopram sessions in bvFTD patients revealed a trend to-
wards an overall effect of citalopram [F(1,8) =4.8,
P = 0.059]. Pairwise t-tests revealed the P3 amplitude to be
signiﬁcantly enhanced during the citalopram session com-
pared to placebo (mean difference = 4.9mV, 1.8 SE
P = 0.03]. The difference in P3 peak amplitudes between
the placebo and citalopram sessions correlated with the
Cambridge Behavioural Inventory stereotypic and motor be-
haviours subscale (Spearman’s rho = 0.54, P = 0.055, one-
tailed), suggesting that the P3 was enhanced more in those
patients who have fewer disinhibited behaviours. There were
no group-wise differences in peak latency between citalopram
and placebo sessions. Table 3 shows mean peak amplitude
and peak latency for the controls and patients groups.
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Figure 1 The regions of grey matter loss in patients with bvFTD compared to the control group. Atrophy is evident in inferior and
middle temporal gyrus, inferior and superior frontal gyrus, bilateral temporal poles and orbitofrontal gyrus. Images are thresholded with a cluster-
based family-wise error correction P5 0.05 (after P5 0.001 voxel-wise uncorrected threshold).
Table 2 Mean reaction times (in ms) and accuracy rates (arcsin transformed in radians, and non-transformed mean
accuracy %) for Go (correct trials) and NoGo (commission errors) trials
Between groups Repeated measures
Controls (n = 20) Placebo (n = 12) Placebo (n = 10) Citalopram (n = 10)
Reaction times (ms)
Go 287.60 (9.58) 475.98 (42.04) 477.84 (46.62) 538.81 (53.33)
NoGo 222.39 (13.07) 369.04 (71.27) 314.64 (52.21) 332.03 (45.79)
Accuracy (rad)
Go 1.5 (0.02) 1.4 (0.03) 1.4 (0.03) 1.34 (0.05)
NoGo 1.35 (0.03) 1.2 (0.13) 1.3 (0.12) 1.2 (0.14)
Accuracy (%)
Go 99 (0.4) 96 (1.2) 96 (1.3) 93 (3.1)
NoGo 94 (1.3) 80 (10.0) 85 (8.9) 87 (10.0)
Standard errors in parentheses.
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The potential differences between waveforms, measured
using time-point by time-point t-tests, substantiate these re-
sults: the bvFTD placebo group compared to controls had a
signiﬁcant increase in onset latency of each of the three
components of interest, reﬂected by reduced amplitudes in
the rising ﬂank of the deﬂections. For the NoGo-N2 at Cz
and the NoGo-P3 at Pz the differences persisted, resulting
in reduced amplitudes throughout the deﬂection.
Comparing the citalopram and placebo sessions revealed
a signiﬁcant difference in the amplitudes of the NoGo-P3
at Pz, which was sustained after 250ms. The signiﬁcant
point-by-point results are illustrated in Fig. 2.
MEG results
During the ﬁrst time window (100 to 200ms, Fig. 3) for
the control group, both Go and NoGo cues activated bilat-
eral visual and prestriate cortex. There were greater source
currents for NoGo versus Go trials in right temporal and
right inferior frontal gyrus (P5 0.05, corrected). NoGo
source activation was signiﬁcantly reduced in the bvFTD
placebo versus controls, within the region of interest
mask of the right IFG and the right temporal lobe,
(P5 0.05, corrected). Exploratory analyses at the liberal
threshold P5 0.001 (uncorrected) revealed a single add-
itional peak difference in the left occipital region between
the controls and bvFTD placebo group. Citalopram did not
change activation in the regions of interest in this early time
window, and there were no signiﬁcant peak differences at
P5 0.001 uncorrected levels.
During the second time window (250 to 350ms, Fig. 3),
in the control group, NoGo compared to Go trials, re-
vealed signiﬁcant clusters in right temporal and right infer-
ior frontal gyrus (P5 0.05, FWE corrected). There was a
trend of reduced activation for NoGo trials in the right IFG
for the bvFTD placebo compared to controls (P = 0.08,
FWE corrected). Exploratory analyses (P5 0.001 uncor-
rected) revealed no additional peak differences between
the controls and bvFTD placebo group. Importantly, in
the citalopram session, right IFG activity was signiﬁcantly
Figure 2 Neurophysiological responses by task and drug conditions. (A) ERPs from three midline electrodes, Fz, Cz and Pz for
successful Go and NoGo trials. Time point 0 denotes the stimulus onset and for convention, negativity is plotted upwards. For NoGo trials, the
bvFTD placebo group (n = 10) show significant reductions in peak amplitudes of all three components of interest: the P2 at Fz, N2 at Cz and P3 at
Pz compared to controls. Citalopram enhanced the P3 at Pz in bvFTD (n = 9), restoring the amplitude towards normal levels compared to
placebo. The black and grey horizontal lines indicate significant differences in onset latencies between controls and bvFTD on placebo, and
citalopram versus placebo, respectively. (B) Topographies of the peak response for the P2, N2 and P3 components during the NoGo trials, with
the Go trials presented at the same latency for comparison.
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increased in the right inferior frontal gyrus region of inter-
est compared to the placebo session for successful NoGo
trials (P5 0.05, FWE corrected, Fig. 4). The exploratory
analyses revealed no additional peak differences between
the citalopram and placebo sessions at P5 0.001
(uncorrected).
For the third time window (400 to 500ms), in controls the
MEG was not sensitive to cortical sources. There were no
signiﬁcant MEG-derived sources localized above P5 0.001
uncorrected. This is in contrast to the observation of a
strong P3 in the EEG data within this time window.
Potential reasons for the insensitivity of MEG to source gen-
erators of the P3 are discussed later, but this null result is
consistent with the MEG literature on P3 responses.
Discussion
The key results of this study demonstrate that in bvFTD, (i)
patients could perform a simple NoGo task to some degree,
Figure 3 sLORETA contrast images for successful NoGo trials, for controls and bvFTD patients on placebo. Controls show
sustained frontal and temporal source responses across the first two time windows (100–200 and 250–350 ms), which are greater for NoGo than
Go trials (P5 0.05 FWE). For the bvFTD placebo group, compared to controls, right frontal and temporal sources are significantly reduced for
NoGo trials from 100–200 ms (P5 0.05 FWE corrected within region of interest), and a trend for a reduced right inferior frontal gyrus response
after 250 ms (P = 0.08 FWE corrected within region of interest). Data plots show peak differences in NoGo source responses between the
control and placebo groups. The regions of interest of right inferior frontal gyrus and right temporal lobe are outlined in black.
Table 3 Peak amplitude (mV) and latency (ms) for NoGo trials
Between groups Repeated measures
Controls (n = 20) Placebo (n = 10) Placebo (n = 9) Citalopram (n = 9)
P2 (Fz)
Peak Amp 6.2 (0.8) 4.0 (1.1) 4.1 (1.2) 6.0 (1.2)
Latency 180 (5.6) 193.4 (7.2) 194 (12.1) 196.7 (7.6)
N2 (Cz)
Peak Amp 2.1 (1.0) 1.6 (1.3) 1.2 (1.6) 1.4 (1.3)
Latency 272.5 (7.7) 260 (9.8) 257.8 (8.0) 269.3 (6.3)
P3 (Pz)
Peak Amp 8.9 (0.9) 2.5 (1.2) 2.5 (0.9) 8.0 (1.9)
Latency 453.4 (7.9) 442.2 (10.0) 439.5 (9.0) 451.11 (11.4)
Standard error in parentheses.
The N2 at Cz for patients did not reach a negative threshold, but in all subjects is calculated as the most negative peak after 200 ms.
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but were impaired behaviourally; (ii) the neurophysiological
markers of successful response inhibition were diminished,
including the absence of the N2 evoked response, and
reduced P3 evoked response, together with attenuated cor-
tical sources in right temporal pole and right inferior fron-
tal gyrus; and (iii) critically, citalopram restored the P3 and
enhanced the cortical response of the right inferior frontal
gyrus during NoGo inhibition.
These neurophysiological changes with disease and the
favourable response to citalopram have important implica-
tions for understanding cognitive dysfunction in bvFTD,
despite the fact that the neurophysiology appeared to be
more sensitive to treatment than behavioural measures
(no signiﬁcant behavioural effects of citalopram were
observed in this group of 12 participants). The results high-
light the impaired neural substrates involved in response
inhibition, including right prefrontal cortex, and the role
of serotonin in regulating cognition. Further, they conﬁrm
that even atrophic and dysfunctional frontal cortical sys-
tems in bvFTD can be functionally restored to some
extent by pharmacological manipulation.
The right inferior frontal gyrus has been speciﬁcally iden-
tiﬁed as an important locus of control during response in-
hibition (Aron et al., 2004, 2014; Konishi et al., 1998,
1999) and in the healthy control subjects a sustained re-
sponse in this region was evident during the NoGo trials.
The attenuation of the response in inferior frontal gyrus in
bvFTD is commensurate with reports that lesions to this
region impair inhibition (Aron et al., 2003; Kopp et al.,
2013). The focal enhanced response in the inferior frontal
gyrus to citalopram suggests that, although this region is
part of the dysfunctional frontotemporal network, its neur-
onal responses can be modulated by serotonergic manipu-
lation. This is consistent with changes in activation of
inferior frontal gyrus after serotonergic modulation in
health (Macoveanu et al., 2013) and in Parkinson’s disease
(Ye et al., 2014). Parkinson’s disease, like bvFTD, is char-
acterized by impulsivity with poor response inhibition
(Weintraub et al., 2010; Bentivoglio et al., 2012). The
problem of impulsivity in Parkinson’s disease is not re-
stricted to patients with impulse control disorders: patients
who do not have impulse control disorders are still impul-
sive on a wide range of measures (Nombela et al., 2014; cf.
Jahanshahi et al., 2015) and this impulsivity has also been
linked to serotonergic depletion (Politis et al., 2010, 2012).
Interestingly, despite clear differences between the clinical
syndromes of Parkinson’s disease and bvFTD, both dis-
orders have dysfunctional frontal cortico-striatal pathways
which may contribute to impulsivity (O’Callaghan et al.,
2013b). The response in both groups to citalopram under-
lines the importance of serotonergic transmission in fron-
tostriatal circuits for response inhibition.
Despite the enhanced response of the inferior frontal
gyrus with citalopram in bvFTD, there was no concomitant
improvement in the NoGo-N2 component of the EEG
evoked potential, which peaks within the same time
window. Indeed, the NoGo-N2 was absent in bvFTD in
both sessions but the NoGo-P3 was signiﬁcantly enhanced
by citalopram, indicating differing sensitivities of these
components to serotonergic modulation. Corroborative
effects of serotonergic transmission in health on the
NoGo-P3, but not NoGo-N2, have been reported: subjects
without the 1019G allele who have putatively elevated
serotonergic levels (Beste et al., 2011) and subjects with
high trait impulsivity (Ruchsow et al., 2008) make more
NoGo commission errors and have a reduced NoGo-P3 to
unpredictable NoGo trials. However, the effects of sero-
tonin in health appear initially to contrast with our results
in bvFTD, in whom increasing serotonin enhanced the P3
and inferior frontal gyrus response. For example, in healthy
individuals with fewer 5HT2A receptors, reducing sero-
tonin availability via acute tryptophan depletion increased
the inferior frontal gyrus response during NoGo trials
(Macoveanu et al., 2013) whereas in our study, increasing
serotonin neurotransmission in the patient group (who likely
have fewer 5HT2A receptors) (Bowen et al., 2008), enhanced
the response in inferior frontal gyrus. In addition, FTD pa-
tients with the long polymorphism of the 5-HTTLPR
(SLC6A4) gene, had a better cognitive proﬁle relative to cor-
tical damage compared to patients with the short allele
(Premi et al., 2015). Together, these studies suggest that
there is an optimal degree of serotonergic transmission for
cognition and behavioural control. Excessive levels of sero-
tonin in health or deﬁciencies in disease both impair perform-
ance (cf. Deakin et al., 2004). This effect is analogous to the
well-established ‘inverted U-shaped’ function relating dopa-
minergic transmission to cognitive and motor control and
regional neuronal activation (Rowe et al., 2008; Cools and
D’Esposito, 2011). The corollary is that citalopram treat-
ment would only be expected to improve the neural systems
for inhibitory control if a subject was in a relatively hypo-
serotonergic state such as bvFTD.
Figure 4 sLORETA contrast of citalopram versus placebo
for successful NoGo trials in patients with bvFTD, during
the 250–350 ms time window. Citalopram enhanced activation
(mean current source density) in the right inferior frontal gyrus
(P5 0.05 FWE corrected within region of interest). Data plot
shows peak difference between citalopram and placebo within the
right inferior frontal gyrus region of interest, for NoGo trials.
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In bvFTD, the reduced amplitudes of the EEG evoked
response and decreased MEG signal in inferior frontal
and temporal cortex reﬂects the loss of speciﬁc neurocog-
nitive functions relevant to NoGo inhibition. Each ERP
component is considered a separate measure of a multifa-
ceted neurocognitive network involved in inhibition. The
N2 is suggested to represent conﬂict monitoring, because
it is present for infrequent Go as well as NoGo trials
(Nieuwenhuis et al., 2003; Donkers and van Boxtel,
2004; Smith et al., 2010; Randall and Smith, 2011). In
contrast, the NoGo-P3 is evident when the inhibition of
planned responses is required (Randall and Smith, 2011),
and is thus considered an index of motor inhibition (Smith
et al., 2008, 2013; Enriquez-Geppert et al., 2010), and also
the evaluation of the inhibitory process (Roche et al.,
2005). The observed reductions in both the ERP compo-
nents in bvFTD may reﬂect impaired detection of behav-
iourally salient low frequency events and impaired motor
inhibition. Critically, serotonin may be only effective in
improving the cognitive processes underlying the P3, con-
sistent with evidence that serotonin manipulations affect
the response inhibition component of NoGo trials
(Macoveanu et al., 2013), and mediate performance moni-
toring during the Go-NoGo task (Evers et al., 2006).
Despite the improvements in neuronal response in the
inferior frontal gyrus and P3 with citalopram, we did not
observe group-level changes in behaviour: patients’ accur-
acy and reaction times did not signiﬁcantly improve across
sessions. It could be considered that NoGo accuracy might
be due to lack of visual focus or attention to the task,
because patients’ Go trial accuracy is also reduced com-
pared to controls. However the proportion of Go errors
(mean 4%) and NoGo accuracy (mean 80%) in the placebo
group does not support this alternative interpretation.
Moreover, the evidence of faster responses when making
a NoGo commission error compared to the reaction time
of Go trials, suggests that the Go trials are inducing a pre-
potent response that must be inhibited on NoGo trials.
Comparably, not all studies of serotonergic interventions
ﬁnd signiﬁcant behavioural effects, even in the presence of
neuronal changes (Rubia et al., 2005; Evers et al., 2006;
Macoveanu et al., 2013). However, some earlier open label
studies of SSRI’s in bvFTD have shown signiﬁcant improve-
ments in behaviour (Boxer and Boeve, 2007). Behavioural
improvement may also be limited without additional res-
toration of the neuronal connectivity of the inferior frontal
gyrus, or sources underlying the NoGo-N2. This raises the
question of whether enhancing additional neuronal regions
would be necessary, and sufﬁcient, to improve disinhibition
in bvFTD. The patients with bvFTD also had impaired
temporal cortical responses, compared to controls, which
were not enhanced by citalopram. It may also be the case
that marked individual differences in the therapeutic re-
sponse mask a group effect (cf. Ye et al., 2014). Ye et al.
revealed that clinical and demographic variables of the pa-
tients, together with measures of the integrity of structural
frontostriatal networks, determined the response to
citalopram. A larger sample of patients with bvFTD, in
combination with genotyping and structural analyses,
may enable stratiﬁcation of patients to examine who is
most likely to beneﬁt from SSRIs at a single-subject behav-
ioural level.
There are important pharmacological issues to consider
when using SSRIs. For example, it has been questioned
whether chronic SSRI administration (42 weeks) has the
same effect as a single dose. Research on fear responses has
suggested differential effects of acute, subchronic or chronic
dosing of SSRI’s in human (cf. Harmer and Cowen, 2013)
and animal models (Burghardt et al., 2004). However, one
should be cautious not to extrapolate from these effects on
affective responses to cognitive and motor tasks, since sero-
tonin has separable effects on the neuronal substrates of
each network (Del-Ben et al., 2005; Cools et al., 2011).
For example, for prefrontal systems mediating reversal
learning or motor response inhibition, there are similar ef-
fects of acute and chronic administration (Almeida et al.,
2010; Bari et al., 2010). Moreover, low dose SSRIs may
induce 5HT1A inhibitory autoreceptors leading to a reduc-
tion in neurotransmission, whereas higher doses induce a
net increase in neurotransmission (Bari et al., 2010). At the
dose of citalopram we used, and for the NoGo inhibition
task dependent on prefrontal cortex, the evidence suggests
a net increase in neurotransmission. Although this is con-
sistent with the behavioural beneﬁt on motor response in-
hibition in Parkinson’s disease (Ye et al 2014), the clinical
beneﬁt of a SSRI for bvFTD disinhibition remains to be
shown in clinical trials with chronic treatment. We suggest
that the serotonergic modulation of frontal inhibitory sys-
tems as revealed by MEG in this study is relevant to be-
haviour, and validates a translational pathway from animal
and pharmacological models towards future larger trials
with clinical endpoints.
One methodological limitation was the source localization
from the MEG data which were restricted to the early time
windows, up to 350ms. Additional cortical regions that gen-
erated the P3 component were not identiﬁed, possibly because
theMEG source localization during this time window is poor.
For example, MEG is relatively insensitive to neuronal
sources in gyral convexities because of their radial orienta-
tion, while EEG is more sensitive to these sources. This may
explain in part why the P3 was not evident in the MEG but
seen clearly in the EEG recording. The localization of the P3
time window using EEG data has identiﬁed bilateral pre-
motor and left inferior frontal regions (Albert et al., 2013),
which accords with results from functional MRI (Smith et al
2013). It should be noted however, that both EEG and MEG
measures are relatively insensitive to deeper sources, such as
those generated in the basal ganglia. Thus it is difﬁcult to
observe direct pharmacological effects in the striatum.
Alternative methods may be more appropriate for examining
contributions of serotonergic manipulation to frontostriatal
interactions. Given the sensitivity of MEG to depth, one must
consider the impact of atrophy on signal-to-noise in clinical
populations, which may increase the distance from cortex to
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sensors by several millimetres. Atrophy and greater cortical
depth in bvFTD cannot explain our most important result,
that citalopram enhances EEG components and MEG source
current density, as cortical depth would be unchanged by
acute drug treatment.
Finally, one must consider the heterogeneity of the pa-
tient population. While disinhibition is a criterion for the
diagnosis, it is not obligatory, and the extent of inhibition
varies considerably between patients and over the course of
the illness. Although we did not select patients according to
their cognitive proﬁle within bvFTD, we cannot rule out
biases resulting from an interaction between impulsivity
and referral or consent to participate. Nonetheless, our pa-
tients manifested typical disinhibition, both on the NoGo
task and neuropsychological tests such as the Hayling Test,
as well as endorsements of symptoms of behavioural disin-
hibition from relatives or carers on the Cambridge
Behavioural Inventory, comparable to previous research
(O’Callaghan et al., 2013b).
In conclusion, we have shown that bvFTD impairs the
neurophysiological signature of critical regions for response
inhibition, and that the response of the right inferior frontal
gyrus can be partially reversed by citalopram. Optimization
of serotonergic strategies to treat disinhibition and other
aspects of impulsivity will require clinical trials, and the
identiﬁcation of factors that determine individual differ-
ences in therapeutic efﬁcacy.
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